Vendor Intelligence Report: Coastal Peptides

Published 3 Jul 2026. 27-page investigative report on who is behind Coastal Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Coastal Peptides is sharply product-specific. Across 26 Finnrick lab tests, Coastal Peptides posts 11 pass / 15 fail — a 42% overall pass rate. Tirzepatide is the defensible bright spot and Retatrutide sits in a variance-managed second tier, while Semaglutide/GLP1-S carries an identity-substitution signal: blind purchases resolved as cagrilintide rather than semaglutide. CJC-1295 shows how weak the lower end of the catalog can get.

The vendor’s COA apparatus does not erase that result. The report traces a GLP1-S COA tied to a vendor-arranged or incentive-sent sample, a separate PT-141 COA-to-vial mismatch complaint, and methodology-sensitivity charts showing why purity screenshots alone cannot substitute for lot matching, fill accuracy, and blind-purchase repeatability.

The accountability picture is thin. Coastal discloses no legal entity, named personnel, or serviceable corporate counterparty; one contact surface preserves a fictitious Hawaii address while adding a Texas-area-code phone and a generic mail.com inbox. The dossier also maps a Coastal-branded X account linking to an unnamed GLP-1 telehealth funnel and a separate storefront using the word official in its domain, with relationship to the subject site unresolved.

Inside the full report:

  • Appendix A with full per-product Finnrick lab data and methodology-divergence charts for all 5 tested products
  • COA chain-of-verification review for GLP1-S and PT-141 artifacts
  • Corporate-registry, WHOIS/RDAP, contact-page, and personnel-search findings
  • Web-infrastructure profile covering WooCommerce, Cloudflare, SliceWP, GA4, and Facebook Pixel anchors
  • Authenticity analysis of coastal.care and officialcoastalpeptides.com, including copycat and parallel-storefront scenarios
  • Payments, shipping, reputation, affiliate-code, and buyer-recourse risk matrix

Risk assessment

  • Semaglutide identity-substitution risk — high: Semaglutide / GLP1-S has 6 Finnrick tests with 0 pass / 6 fail; five blind-purchased samples were identified as cagrilintide.
  • Non-representative COA / product-verification risk — high: GLP1-S COA is tied to an incentive-sent sample while blind semaglutide purchases failed; PT-141 cap-color mismatch was also reported.
  • BPC-157 and CJC-1295 quality-variance risk — medium: BPC-157 and CJC-1295 each passed 2 of 5 Finnrick tests; BPC-157 also had a field-noted 10mg vial containing 12.6mg.
  • Retatrutide variance risk — medium: Retatrutide / GLP3-R is comparatively stronger but still recorded 3 pass / 2 fail across 5 Finnrick tests.
  • Anonymous-operator / buyer-recourse risk — medium: No legal entity or personnel identified; site displays a fictitious address, Texas-area-code phone, and generic mail.com contact surface.
  • Brand-confusion / copycat-verification risk — medium: officialcoastalpeptides.com operates as a similar separate storefront with unresolved relationship and no official-channel list from Coastal.
  • Payment-recourse risk — medium: Cash App and emailed payment links reduce chargeback leverage if a shipment is missing, mislabeled, or disputed.
  • Reputation-signal reliability risk — medium: Trustpilot profile was removed for guideline violations, and Peptide Critic’s limited review record sits alongside a disclosed affiliate relationship.